Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
Holding FATE?
Track your performance easily
FATE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.59 - $8.83
Previous Close$1.68
Volume10.14M
Average Volume (3M)2.71M
Market Cap
$189.06M
Enterprise Value-$8.88M
Total Cash (Recent Filing)$296.92M
Total Debt (Recent Filing)$98.98M
Price to Earnings (P/E)―
Beta3.30
Next Earnings
Mar 03, 2025EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding113,894,333
10 Day Avg. Volume3,714,903
30 Day Avg. Volume2,710,224
Standard Deviation0.25
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.53
Price to Sales (P/S)14.06
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.66
Enterprise Value/Gross Profit-0.14
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$5.50Price Target Upside227.38% Upside
Rating ConsensusHold
Number of Analyst Covering12
Fate Therapeutics News
PremiumCompany Announcements
Fate Therapeutics Announces Leadership Transition for 2025
Bulls Say, Bears Say
Bulls Say
Clinical ProgressPositive clinical proof-of-mechanism for the company’s off-the-shelf cell therapy-enabling allo-defense receptor platform in patients with r/r B-cell lymphoma treated with FT522 supports potential development for the NK cell product in auto-immune disease without lymphodepleting chemotherapy.
Financial PerformanceFATE reported 3Q24 operating results with a net loss per share better than the consensus estimate.
Regulatory And Research DevelopmentsThe FDA has allowed FATE's IND application to initiate a Phase 1 study for FT522 in B-cell mediated autoimmune diseases.
Bears Say
Clinical DataAdditional data is needed from more patients to make further changes to the evaluation model after initial clinical data of FT819.
ProfitabilityReturn on Equity is notably negative, indicating the company is currently not profitable.
Regulatory TimelinesPotential regulatory timelines for FATE programs have been pushed to 2027+, as lead programs remain in early stages of development.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $1.59 and its highest was $8.83 in the past 12 months.
What is Fate Therapeutics’s market cap?
Currently, no data Available
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 71 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.416 by $0.016.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -$0.44.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 113,894,330 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.416. Following the earnings report the stock price went down -8.824%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Among the largest hedge funds holding Fate Therapeutics’s share is Deerfield Management Company, LP. It holds Fate Therapeutics’s shares valued at 12M.
---
Fate Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.50 (227.38% Upside)
$5.50 (227.38% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.09%
12-Months-Change
Fundamentals
Return on Equity
-46.59%
Trailing 12-Months
Asset Growth
-8.98%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
---
FATE Earnings Call
Q1 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials, particularly with FT819 and FT522, alongside a strong financial position. However, revenue growth remains limited and operating expenses are high, suggesting a balanced outlook with promising clinical achievements countered by financial challenges.Read More>---
FATE Stock 12 Month Forecast
Average Price Target
$5.50
▲(227.38% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering FATE
1 Year
1 Year Success Rate
3/15 ratings generated profit
1 Year Average Return
-18.73%
assigned a buy rating 11 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -18.73% per trade.
---